{"version":"1.0","provider_name":"Canadian Drug Policy Coalition","provider_url":"https:\/\/new.drugpolicy.ca\/fr\/","author_name":"admin","author_url":"https:\/\/new.drugpolicy.ca\/fr\/author\/admin\/","title":"Lifesaving Heroin Assisted Treatment Dealt Serious Blow - Canadian Drug Policy Coalition","type":"rich","width":600,"height":338,"html":"<blockquote class=\"wp-embedded-content\" data-secret=\"iwAiSuR3aS\"><a href=\"https:\/\/new.drugpolicy.ca\/fr\/lifesaving-heroin-assisted-treatment-dealt-serious-blow\/\">Lifesaving Heroin Assisted Treatment Dealt Serious Blow<\/a><\/blockquote><iframe sandbox=\"allow-scripts\" security=\"restricted\" src=\"https:\/\/new.drugpolicy.ca\/fr\/lifesaving-heroin-assisted-treatment-dealt-serious-blow\/embed\/#?secret=iwAiSuR3aS\" width=\"600\" height=\"338\" title=\"&#8220;Lifesaving Heroin Assisted Treatment Dealt Serious Blow&#8221; &#8212; Canadian Drug Policy Coalition\" data-secret=\"iwAiSuR3aS\" frameborder=\"0\" marginwidth=\"0\" marginheight=\"0\" scrolling=\"no\" class=\"wp-embedded-content\"><\/iframe><script>\n\/*! This file is auto-generated *\/\n!function(d,l){\"use strict\";l.querySelector&&d.addEventListener&&\"undefined\"!=typeof URL&&(d.wp=d.wp||{},d.wp.receiveEmbedMessage||(d.wp.receiveEmbedMessage=function(e){var t=e.data;if((t||t.secret||t.message||t.value)&&!\/[^a-zA-Z0-9]\/.test(t.secret)){for(var s,r,n,a=l.querySelectorAll('iframe[data-secret=\"'+t.secret+'\"]'),o=l.querySelectorAll('blockquote[data-secret=\"'+t.secret+'\"]'),c=new RegExp(\"^https?:$\",\"i\"),i=0;i<o.length;i++)o[i].style.display=\"none\";for(i=0;i<a.length;i++)s=a[i],e.source===s.contentWindow&&(s.removeAttribute(\"style\"),\"height\"===t.message?(1e3<(r=parseInt(t.value,10))?r=1e3:~~r<200&&(r=200),s.height=r):\"link\"===t.message&&(r=new URL(s.getAttribute(\"src\")),n=new URL(t.value),c.test(n.protocol))&&n.host===r.host&&l.activeElement===s&&(d.top.location.href=t.value))}},d.addEventListener(\"message\",d.wp.receiveEmbedMessage,!1),l.addEventListener(\"DOMContentLoaded\",function(){for(var e,t,s=l.querySelectorAll(\"iframe.wp-embedded-content\"),r=0;r<s.length;r++)(t=(e=s[r]).getAttribute(\"data-secret\"))||(t=Math.random().toString(36).substring(2,12),e.src+=\"#?secret=\"+t,e.setAttribute(\"data-secret\",t)),e.contentWindow.postMessage({message:\"ready\",secret:t},\"*\")},!1)))}(window,document);\n\/\/# sourceURL=https:\/\/new.drugpolicy.ca\/wp-includes\/js\/wp-embed.min.js\n<\/script>\n","thumbnail_url":"https:\/\/www.canadiandrugpolicy.ca\/wp-content\/uploads\/2013\/10\/RonaAmbrose-Attribution-Number10-changes_Blog_415x415px-S.jpg","thumbnail_width":415,"thumbnail_height":415,"description":"By Connie Carter and Susan Boyd On October 3, 2013, federal Health Minister Rona Ambrose announced new regulations that became effective immediately to prevent Health Canada\u2019s Special Access Programme from approving the use of prescribed diacetylmorphine* as a treatment for addiction for a small number of patients finishing the clinical trial SALOME, in Vancouver, BC. [&hellip;]"}